Nasdaq · CIK 0001826667
TLSI TriSalus Life Sciences, Inc.
Insider trading from SEC Form 4. Last filing 5 d ago. Close $4.06 on Oct 9, 2026, +61% from the 52-week low and -46% from the high.
Last 90 days
Net insider value
-$4,113
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$4,113 by 3 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
TLSIOct 9, 2026 · close 4.06
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at TriSalus Life Sciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Bryan F. Cox Chief of Research sell | $1,299 296 shares | -0% | +74% from low-42% from high | |
| 30Weak | Richard Marshak Chief Commercial Officer sell | $1,427 325 shares | -0% | +74% from low-42% from high | |
| 30Weak | Jennifer Stevens Chief Regulatory Officer sell | $1,387 316 shares | -0% | +74% from low-42% from high | |
| 30Weak | Bryan F. Cox Chief of Research sell | $25k 4,764 shares | -4% | +44% from low-10% from high | |
| 30Weak | Jodi Devlin Chief of Clinical Operations sell | $25k 4,764 shares | -8% | +44% from low-10% from high | |
| 36Weak | Richard Marshak Chief Commercial Officer sell | $34k 6,597 shares | -9% | +44% from low-10% from high | |
| 41Moderate | Jennifer Stevens Chief Regulatory Officer sell | $45k 8,704 shares | -10% | +44% from low-10% from high | |
| 15Weak | Bryan F. Cox CHIEF SCIENTIFIC & MANUFACT. sell | $1,394 314 shares | -0% | - | |
| 20Weak | Frankenius Equity AB owner buy | $250k 62,972 shares | +1% | - | |
| 30Weak | Arjun JJ Desai director sell | $111k 30,000 shares | -11% | - | |
| 26Weak | Mats Wahlstrom director, owner buy | $23k 5,000 shares | +47% | - | |
| 29Weak | Mats Wahlstrom director, owner buy | $47k 10,727 shares | - | - |
Transactions
The last 40 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Richard Marshak Chief Commercial Officer | SOpen-market sale Common Stock | -325 | $4.39 | $1,427 | 127,994 | 5 d ago |
| Oct 5, 2026 | Jennifer Stevens Chief Regulatory Officer | SOpen-market sale Common Stock | -316 | $4.39 | $1,387 | 123,794 | 5 d ago |
| Oct 5, 2026 | Mary T Szela CEO and President | FTax withholding Common Stock | -2,693 | $4.38 | $12k | 1,074,990 | 5 d ago |
| Oct 5, 2026 | Bryan F. Cox Chief of Research | SOpen-market sale Common Stock | -296 | $4.39 | $1,299 | 162,805 | 5 d ago |
| Jun 12, 2025 | Arjun JJ Desai director | AGrant or award Director Stock Option (right to buy)derivative | +15,000 | $0.00 | $0 | 65,000 | Jun 27, 2025 |
| Jun 12, 2025 | Gary B. Gordon director | AGrant or award Director Stock Option (right to buy)derivative | +15,000 | $0.00 | $0 | 56,250 | Jun 27, 2025 |
| Jun 12, 2025 | Kerry R Hicks director | AGrant or award Director Stock Option (right to buy)derivative | +15,000 | $0.00 | $0 | 89,222 | Jun 27, 2025 |
| Jun 12, 2025 | David J Matlin director | AGrant or award Director Stock Option (right to buy)derivative | +15,000 | $0.00 | $0 | 65,000 | Jun 27, 2025 |
| Jun 12, 2025 | Sean Murphy director | AGrant or award Director Stock Option (right to buy)derivative | +15,000 | $0.00 | $0 | 554,681 | Jun 27, 2025 |
| Jun 12, 2025 | Mats Wahlstrom director | AGrant or award Director Stock Option (right to buy)derivative | +15,000 | $0.00 | $0 | 200,945 | Jun 27, 2025 |
| Jun 12, 2025 | William Valle director | AGrant or award Director Stock Option (right to buy)derivative | +15,000 | $0.00 | $0 | 56,250 | Jun 27, 2025 |
| May 19, 2025 | James Emmett Young Chief Financial Officer | AGrant or award Common Stock | +13,175 | $5.18 | $68k | 49,663 | May 21, 2025 |
| May 19, 2025 | Jennifer Stevens Chief Regulatory Officer | AGrant or award Common Stock | +28,455 | $5.18 | $147k | 86,344 | May 21, 2025 |
| May 19, 2025 | Sean Murphy director | AGrant or award Common Stock | +44,884 | $5.18 | $232k | 123,989 | May 21, 2025 |
| May 19, 2025 | Richard Marshak Chief Commercial Officer | AGrant or award Common Stock | +21,428 | $5.18 | $111k | 75,698 | May 21, 2025 |
| May 19, 2025 | Jodi Devlin Chief of Clinical Operations | AGrant or award Common Stock | +24,131 | $5.18 | $125k | 57,528 | May 21, 2025 |
| May 19, 2025 | Bryan F. Cox Chief of Research | AGrant or award Common Stock | +15,722 | $5.18 | $81k | 124,179 | May 21, 2025 |
| May 19, 2025 | Richard Marshak Chief Commercial Officer | SOpen-market sale Common Stock | -6,597 | $5.18 | $34k | 69,101 | May 21, 2025 |
| May 19, 2025 | Bryan F. Cox Chief of Research | SOpen-market sale Common Stock | -4,764 | $5.18 | $25k | 119,415 | May 21, 2025 |
| May 19, 2025 | Jennifer Stevens Chief Regulatory Officer | SOpen-market sale Common Stock | -8,704 | $5.18 | $45k | 77,640 | May 21, 2025 |
| May 19, 2025 | Jodi Devlin Chief of Clinical Operations | SOpen-market sale Common Stock | -4,764 | $5.18 | $25k | 52,764 | May 21, 2025 |
| Feb 18, 2025 | Bryan F. Cox CHIEF OF RESEARCH | AGrant or award Common Stock | +11,450 | $0.00 | $0 | 108,457 | Feb 19, 2025 |
| Feb 18, 2025 | Jodi Devlin Chief of Clinical Operations | AGrant or award Common Stock | +5,272 | $0.00 | $0 | 33,397 | Feb 19, 2025 |
| Feb 10, 2025 | Frankenius Equity AB owner | JOther Series A Convertible Preferred Stockderivative | +205,853 | $0.00 | $0 | 435,853 | Feb 11, 2025 |
| Jan 29, 2025 | Gary B. Gordon director | AGrant or award Director Stock Option (right to buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Jan 31, 2025 |
| Jan 29, 2025 | Gary B. Gordon director | AGrant or award Director Stock Option (right to buy)derivative | +6,250 | $0.00 | $0 | 6,250 | Jan 31, 2025 |
| Jan 27, 2025 | Bryan F. Cox CHIEF OF RESEARCH | AGrant or award Common Stock | +10,625 | $0.00 | $0 | 97,007 | Jan 29, 2025 |
| Jan 27, 2025 | Jodi Devlin Chief of COMMERC. OPERATIONS | AGrant or award Common Stock | +10,625 | $0.00 | $0 | 28,125 | Jan 29, 2025 |
| Jan 27, 2025 | Bryan F. Cox CHIEF OF RESEARCH | AGrant or award Employee Stock Option (right to buy)derivative | +63,750 | $0.00 | $0 | 63,750 | Jan 29, 2025 |
| Jan 27, 2025 | Jodi Devlin Chief of COMMERC. OPERATIONS | AGrant or award Employee Stock Option (right to buy)derivative | +63,750 | $0.00 | $0 | 63,750 | Jan 29, 2025 |
| Jan 2, 2025 | Liselotte Hyveled director | AGrant or award Common Stock | +10,040 | $0.00 | $0 | 10,040 | Jan 6, 2025 |
| Dec 17, 2024 | Frankenius Equity AB owner | POpen-market purchase Common Stock | +62,972 | $3.97 | $250k | 6,230,748 | Dec 19, 2024 |
| Dec 17, 2024 | Mats Wahlstrom director, owner | AGrant or award Common Stock | +25,188 | $3.97 | $100k | 40,915 | Dec 19, 2024 |
| Oct 5, 2024 | Bryan F. Cox CHIEF SCIENTIFIC & MANUFACT. | SOpen-market sale Common Stock | -314 | $4.44 | $1,394 | 86,382 | Dec 19, 2024 |
| Dec 10, 2024 | Arjun JJ Desai director | SOpen-market sale Common Stock | -30,000 | $3.69 | $111k | 247,127 | Dec 12, 2024 |
| Nov 22, 2024 | Mats Wahlstrom director, owner | POpen-market purchase Common Stock | +5,000 | $4.55 | $23k | 15,727 | Nov 25, 2024 |
| Nov 20, 2024 | Mats Wahlstrom director, owner | POpen-market purchase Common Stock | +2,040 | $4.16 | $8,486 | 2,040 | Nov 22, 2024 |
| Nov 21, 2024 | Mats Wahlstrom director, owner | POpen-market purchase Common Stock | +8,687 | $4.44 | $39k | 10,727 | Nov 22, 2024 |
| Nov 14, 2024 | Richard Marshak SR.VP, CORP. DEV. & STRATEGY | AGrant or award Common Stock | +6,875 | $0.00 | $0 | 34,126 | Nov 15, 2024 |
| Nov 14, 2024 | Richard Marshak SR.VP, CORP. DEV. & STRATEGY | AGrant or award Employee Stock Option (right to buy)derivative | +41,250 | $0.00 | $0 | 41,250 | Nov 15, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Bryan F. CoxChief of Research
- Arjun JJ Desaidirector
- Jodi DevlinChief of Clinical Operations
- Frankenius Equity ABowner
- Gary B. Gordondirector
- Kerry R Hicksdirector
- Liselotte Hyveleddirector
- David J Matlindirector
- Richard MarshakChief Commercial Officer
- Sean Murphydirector
- Jennifer StevensChief Regulatory Officer
- Mary T SzelaCEO and President
- William Valledirector
- Mats Wahlstromdirector, owner
- James Emmett YoungChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.